Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Oct 2 · below the Ichimoku cloud · RSI 44 · MACD above its signal
None of the 29 investors followed here reported a position in PBSV in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PBSV trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for PBSV.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.7 | -16.9 | 4.1 | -2.0 | 14.0 | 0.0 | -26.3 | 28.6 | -16.7 | -6.7 | −30.0% | ||
| 2025 | 9.1 | -6.7 | -10.7 | -8.0 | 8.7 | 2.0 | 19.6 | -1.6 | 11.7 | -19.4 | 7.4 | 3.4 | +9.1% |
| 2024 | -8.6 | -4.2 | -7.6 | -12.9 | -5.4 | -7.1 | 0.0 | -6.2 | 6.6 | -10.8 | -15.5 | 12.2 | −47.6% |
| 2023 | 31.6 | -15.4 | 6.8 | 8.5 | -21.6 | 12.5 | 18.9 | -4.7 | 1.0 | -17.5 | 4.7 | 18.0 | +32.9% |
| 2022 | -5.8 | -4.1 | -3.2 | 2.2 | 2.2 | -13.8 | -3.7 | 2.6 | 0.0 | 7.5 | -10.5 | 2.6 | −23.3% |
| 2021 | -17.2 | 25.0 | -18.0 | 4.9 | -3.9 | 7.3 | -11.3 | -2.5 | -12.2 | 2.0 | -1.9 | 2.0 | −29.0% |
| 2020 | -2.3 | 0.0 | -3.5 | 3.7 | -3.5 | 3.7 | 17.6 | 5.0 | 22.9 | 0.0 | 8.5 | 3.6 | +66.7% |
| 2019 | 2.0 | 4.9 | -0.9 | 1.9 | -3.7 | -9.6 | -4.3 | 5.6 | 4.2 | -11.1 | -17.0 | 19.2 | −13.0% |
| 2018 | 23.1 | -12.5 | -5.4 | 13.2 | 0.0 | 6.7 | -3.1 | 3.2 | 43.8 | 14.1 | 8.6 | -12.3 | +92.3% |
| 2017 | -12.1 | -8.0 | -12.5 | 0.0 | -7.1 | 6.2 | -2.9 | -10.4 | -45.0 | 51.5 | 4.0 | 0.0 | −47.5% |
| 2016 | -17.0 | -9.6 | 13.3 | -2.4 | 7.2 | 4.5 | -4.3 | 1.1 | -5.6 | 11.8 | -8.4 | 13.8 | −1.0% |
| 2015 | 0.0 | 0.0 | -1.5 | -8.6 | 6.8 | -9.6 | -11.5 | 3.0 | -1.0 | -8.8 | 1.1 | 6.4 | −23.1% |
| 2014 | -2.9 | 0.0 | -11.9 | -7.3 | 6.1 | -25.7 | -4.6 | -5.6 | 11.1 | -3.1 | 0.0 | 3.2 | −37.5% |
| 2013 | 16.0 | 49.4 | -21.5 | -2.0 | 10.0 | 16.4 | 0.0 | 17.2 | 6.7 | 1.9 | 26.4 | 1.0 | +177.3% |
| 2012 | 4.3 | -1.4 | 18.1 | 4.7 | -4.5 | -1.2 | -1.2 | -3.6 | 3.7 | -3.6 | -11.3 | 5.6 | +7.1% |
| 2011 | 34.6 | -14.3 | 16.7 | 0.0 | -2.9 | 20.6 | 0.0 | -2.4 | 57.5 | 23.8 | -7.7 | -2.8 | +169.2% |
| 2010 | -51.5 | 25.0 | 50.0 | 16.7 | 5.7 | 0.0 | -8.1 | -26.5 | 16.0 | 6.9 | -16.1 | 0.0 | −21.2% |
| 2009 | 0.0 | -38.0 | 77.4 | -45.5 | 0.0 | 33.3 | -22.5 | 54.8 | 0.0 | -31.2 | -9.1 | 10.0 | −34.0% |
| 2008 | -7.7 | -1.7 | -28.8 | 42.9 | 5.0 | 1.6 | -6.2 | -15.0 | -5.9 | -43.7 | 85.2 | 0.0 | −23.1% |
| 2007 | 37.2 | -5.1 | 0.0 | 33.9 | 32.0 | -48.5 | 27.5 | +51.2% |
Buy / hold / sell counts
Pharma-Bio Serv, Inc. operates as a regulatory affair, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company offers a broad range of technical compliance consulting services, including regulatory affairs, quality assurance, compliance, technology transfer, validation, engineering, project management, and process support. It serves pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.